Siehe http://www.uct.ac.za/mondaypaper/?id=8506 :
ZitatAfter all, MenAfriVac has the potential to wipe out meningitis in the infamous 'meningitis belt' in the north of Africa, a strip of 25 countries that stretches from Senegal in the west to Ethiopia and Eritrea in the east. Some 450 million people live in this belt, said to account for the bulk of the world's meningitis epidemics, which hit the region every seven to 14 years. (It's the dry seasons from December to June, the dust winds, cold nights and upper respiratory tract infections, scientists believe, that make people in this region especially susceptible to infections.)
MenAfriVac is designed specifically to provide protection against group A Neisseria meningitidis, the bacterium responsible for nearly 90% of all meningococcal infections in the belt.
So lange wie kein Matthias-Rath-Lookalike oder Milchwirt vorbeikommt, koennte hier richtig vielen Menschen geholfen werden.